Alleviant ALV1 System klinisk forsøg for hjertepatienter

Clinical Trial Overview: This study evaluates the safety and efficacy of the Alleviant ALV1 System, a no-implant interatrial shunt device, in patients with heart failure and reduced ejection fraction (HFrEF). The trial aims to assess whether this innovative device can improve outcomes for HFrEF patients by creating a shunt between the atria, potentially reducing left atrial pressure and improving symptoms.

Study Design: This is a randomized, double-blind, crossover assignment interventional study involving 350 participants. Patients will be divided into two groups: one receiving the Alleviant ALV1 System procedure and another undergoing a sham-control procedure. The primary endpoint is a composite of all-cause mortality, cardiac transplantation, permanent LVAD implantation, and heart failure events at 12 months.

Patient Eligibility: Participants must have LVEF ≤40%, NYHA class II-III or ambulatory IV heart failure, and be on stable, optimal medical therapy. Exclusion criteria include advanced heart failure, life expectancy <12 months, and right heart dysfunction.

Potential Impact: If successful, this device could offer a novel treatment option for HFrEF patients who remain symptomatic despite optimal medical therapy. The no-implant approach may reduce risks compared to traditional surgical interventions. The study is being conducted at multiple centers, with principal investigators from Mount Sinai and Tufts Medical Center leading the research.

Trial Details: The study begins in March 2025 with primary completion expected by December 2028. This investigational device could potentially address an unmet need in heart failure management by providing a less invasive option for patients with reduced ejection fraction.